Biotech Values

[rfj1862]

More challenges for biotech investors are not necessarily a bad thing, as you suggested in your bottommost paragraph.

Yes. When I was referring to poorly informed retail investors I wasn't referring to myself. The only thing I am actually well-informed on is pharma and biotech

My point here is that the average retail investor--the kind that doesn't know what an end point is--is just going to get mugged in this environment. Even worse than before.